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Ventricular remodeling, decreased left ventricular systolic func-
tion, and heart failure have been associated with poor long-term
outcomes after myocardial infarction [1,2]. Thus, it is critical to know
the pathophysiological alterations involved in these processes for
myocardial infarction management.
A rat coronary artery ligation leads to a wide range of infarct size,
cardiac remodeling and left ventricular dysfunction. In addition, it is
accepted that the coronary occlusion consequences are closely
related to infarction size, which is a powerful determinant of
survival [3], ventricular remodeling [4], and cardiac systolic function
[5]. In order to determine the association between infarct size and
outcomes after coronary occlusion, the animals were divided into
three groups (small, moderate or large infarct size), but this division
was not homogeneous among the studies because the animals were
randomly placed in the groups. Consequently, the infarct size that is
necessary to determine morphological, functional, and clinical
alterations after the coronary occlusion, still needs to be determined.
The present study was carried out to determine the critical infarct size to
induce ventricular remodeling, cardiac dysfunction, and heart failure in a
rat model.
Myocardial infarction was induced following the method
described previously [6]. Six months after surgery, Sham (n=67)
and infarcted animals (n=166) were subjected to transthoracic
echocardiography, and euthanized the next day.
The echocardiographic exams and morphometric analysis were
performed as described previously [6,7]. The left ventricular
remodeling was deﬁned as the infarcted values of the left ventricular
end-diastolic cavity areas with a difference of N2 and standard
deviations above Sham group mean. The systolic dysfunction was
deﬁned as the infarcted values of posterior wall shortening velocity
(PWSV) with a difference of b2 and standard deviations under Sham
group mean. The diastolic dysfunction was deﬁned as the infarcted
values of E/A ratio with a difference of N2 and standard deviations
above Sham group mean.
The variables utilized to determine heart failure included
pleuropericardial effusion, left atrial thrombi, ascites, or right
ventricular hypertrophy (right ventricle weight-to-body weight
ratio N0.8 mg/g) [8].
An infarct size cut-off valuewas derived from the receiver-operating
characteristic (ROC) curve according to the infarct size value to
maximize sensitivity, speciﬁcity, and predictivity values in order to
anticipate remodeling, cardiac dysfunctions, and heart failure. The bias
between histology and echocardiogram in the infarct size assessment
was evaluated by Bland & Altman.
After a six-month follow-up, the infarct size in the infarcted
animals ranged from 18.5% to 57%, with an average of 40±9%
assessed by histology, and 42±9% assessed by echocardiogram, and
bias between the methods at −1.15%.
The infarct size cut-off values were 36% (area under ROC curves
(AUC): 0.70; 95% CI: 0.61-0.78; p=0.017) for ventricular remodel-
ing; 38% (AUC: 0.72; 95% CI: 0.64-0.80; p=0.001) for PWSV; 44%
(AUC: 0.72; 95% CI: 0.64–0.79; pb0.001) for E/A ratio and 40% (AUC:
0.65; 95% CI: 0.56-0.73; p=0.004) for heart failure.
Among the infarcted rats, 93% presented ventricular remodeling;
86% showed systolic dysfunction; 47% presented diastolic dysfunc-
tion; and 66% had heart failure.
The knowledge of the critical infarct size necessary to induce
remodeling, cardiac dysfunction, and heart failure in this model can
be extremely useful, since infarct size can be early estimated after
the coronary occlusion by non invasive methods, such as echocar-
diogram. In the present study, the infarct size was determined by
histology, even though this measurement had low bias when
compared to infarct size measured by echocardiography.
In conclusion, the identiﬁcation of the critical infarct size to
induce ventricular remodeling, cardiac dysfunction, and heart failure
might be particularly useful in longitudinal studies about therapeu-
tic and pathophysiological aspects following coronary occlusion. Our
data indicate that the minimum infarct size to cause these
morphological, functional and clinical abnormalities is 36%, 38%,
and 40%, respectively.
The authors of this manuscript have certiﬁed that they comply
with the Principles of Ethical Publishing in the International Journal
of Cardiology (Shewan and Coats 2010;144:1–2).
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Several studies have shown that C-reactive protein (CRP) contributes
to the pathogenesis of diabetes mellitus type 2 (DM2) and predicts its
incidence [1]. Further evidence suggests that CRP is not just an acute
phase protein, but rather a mediator of atherogenesis, serving as a
marker of acute coronary syndromes, as well as predicting events after
interventional procedures [2,3]. Genetic polymorphisms are nowadays
considered to be potential regulators of several biomarkers in patients
with or without coronary artery disease (CAD) [4] and speciﬁcally CRP
gene polymorphisms have been proposed to modulate CRP levels and
probably the risk for CAD events in healthy individuals. There is also
susceptibility for a role of CRP gene polymorphisms in the development
of DM2 by increasing CRP levels [5]. However, the results regarding a
speciﬁc CRP gene polymorphism such as the adenine/guanine 3872
(A3872G) on CRP levels seem to be conﬂicting. In the present study we
examined the impact of the A3872G polymorphism in CRP gene, on the
risk for DM or CAD, on CRP levels, glucose levels, haemoglobin A1c
(HbA1c) and the duration of diabetes in patients with documented
diabetes mellitus.
The study population consisted of 427 patients with DM2
(documented for CAD or not) and 227 healthy controls. Subjects
were characterized as patients with DM2 if fasting plasma glucose
levels were ≥126 mg/dl, or 2-hour post glucose loading plasma
levels ≥200 mg/d according to the American Diabetes Association
[6]. Risk factors were evaluated as described previously [4,7].
Coronary artery disease was evaluated by coronary angiography
(stenosisN50%) or positive exercise test, while the absence of CAD
was considered in those patients presenting with normal electro-
cardiogram, absence of symptoms, negative exercise test and/or
normal coronary angiography. Exclusion criteria were any acute or
chronic inﬂammatory disease, malignancies, recent acute coronary
event during the last 2 months, renal or liver failure. The study was
approved by the Institutional Ethics Committees, and an informed
consent was given by all the participants.
Venous blood samples were centrifuged at 3500 rpm at 4 °C for
15 min, and plasma or serum was collected and stored at −80 °C
until assayed. Serum concentrations of total cholesterol, high density
lipoprotein cholesterol, low density lipoprotein cholesterol and were
determined by using colorimetric enzymatic method in a Technicon
automatic analyzer RA-1000 (Dade-Behring Marburg GmbH, Mar-
burg, Germany). Serum CRP levels were measured by particle-
enhanced immunonephelometry (N Latex; Dade-Behring Marburg
GmbH). Moreover glucose levels were measured with standard
techniques and HbA1c by an automated analyzer using the HPLC
technique (HA8160, ADAMS A1c, ARKRAY, Inc. Kyoto, Japan).
Genomic DNA was extracted from 2 to 5 ml of whole blood using
standard methods (QIAamp DNA blood kit; Qiagen, West Sussex,
UK). For the detection of A3872G (rs1205) polymorphism on CRP
gene, we used primer pairs to amplify a part of the gene by
Polymerase Chain Reaction (PCR) with the following ﬂanking
intronic primers: rs1205F: 5′cacaagagtggacgtgaa-3′ and rs1205R:5′
cttatagacctgggcagt-3′. The resulting product (630 bps) was digested
by HpyCH4III restriction endonuclease (3 h at 37°C and resolution by
electrophoresis at 1% agarose gel). Digested fragments were
visualized after ethidium bromide staining under ultraviolet light.
Allele frequencies were tested with chi-square test, if conformed
to Hardy–Weinberg equilibrium proportions. Our priori power
analysis had shown that this population (654 cases) is capable to
show signiﬁcant differences between the study parameters such as
the duration and the risk of diabetes. More speciﬁcally, the sample
size of our study was calculated according to the applied priori
power analysis based on mean values of duration/years (Mann–
Whitney) collected from pilot data. Accordingly a total sample size of
~425 participants (divided into two inequal groups with a propor-
tion of 1/5 approximately), was adequate to reveal an effect size of
0.35, achieving the desirable statistical power of N80%, at a preﬁxed
0.05 type I error. Furthermore, (as regards the risk of DM2) the
power analysis with a sample size of 321 subjects was adequate to
reveal an effect size of 0.3, achieving the desirable statistical power
⁎ Corresponding author at: Athens University Medical School, Hippokration Hospital,
Vasilissis Soﬁas 114, 115 28, Athens, Greece.
E-mail address: drtousoulis@hotmail.com (D. Tousoulis).
1 These authors contributed equally to this work.
243Letters to the Editor
Open access under the Elsevier OA license.
